Acute methotrexate-induced leukoencephalopathy: MRI findings

Clinical History

A 10-year-old female patient with acute lymphoblastic leukaemia who just finished the third cycle of intrathecal administration of methotrexate, presented with acute onset of right hemiparesis.

Imaging Findings

Eight hours after the beginning of symptoms, magnetic resonance (MR) depicts the presence of focal and symmetrical regions of restricted diffusion on DWI images and ADC maps, seen on both centrum semiovale and both corona radiata, as well as on the splenium of corpus callosum (Fig. 1). On T2-weighted images these lesions show high signal intensity, while on Flair there is mild ring hyperintensity (Fig. 2). Iso to hypointensity is seen on T1-weighted images. After intravenous administration of gadolinium there is no evident enhancement (Fig. 3).
Two months after the acute stage, follow-up images demonstrate no restriction on DWI and ADC maps on previously affected areas (Fig. 4). There is only slight hyperintensity on T2 and FLAIR, representing gliosis (Fig. 5). The patient was asymptomatic.

Discussion

The use of intrathecal administration of methotrexate is an essential component in the chemotherapeutic treatment of acute lymphoblastic leukaemia [1, 2] to prevent and treat the affection of the central nervous system [2].
Renal toxicity is the most common and significant side effect of methotrexate; other side effects include: diarrhoea, mucositis, leukopaenia, hepatotoxicity, dry eyes, pleuritis, osteoporosis, and occasionally interstitial pneumonitis [3].
Acute leukoencephalopathy is observed in 5-18% of children undergoing this therapy [1, 4, 5], though some authors reported it as a rare manifestation, aseptic meningitis being the most frequent acute complication in this case [3].
Risk factors for this neurotoxic effect include: high dose treatment, intrathecal administration, young age, and associated cranial irradiation [1, 4, 5].
The pathophysiology of methotrexate-related neurotoxicity is unclear, but it is believed that it has a direct neurotoxic effect, generating cytotoxic oedema [2, 4]. Although this is seen on early MR as areas of altered signal intensity on DWI images [1, 2, 3, 4, 5], this acute cellular injury is not always irreversible [1, 3, 4, 5]. In patients undergoing cranial irradiation, this adverse effect may be more severe and irreversible [1]. Some authors reported fatal cases of methotrexate-induced neurotoxicity [2].
Clinical manifestations of acute neurotoxicity often include: seizure, transient ischaemic attack, encephalopathy, ataxia, myelopathy [4, 5] and stroke-like focal deficits [3]. Nausea, vomiting, headache, somnolence and mental confusion have also been reported [2].
On MR images these lesions are not confined to typical vascular territories and usually appear as focal areas of restricted diffusion on DWI, with high signal intensity on Flair and T2-weighted images [1, 2, 3, 4, 5] and no gadolinium enhancement [1]. Generally they affect periventricular white matter, more often both centrum semiovale [4, 5] and both corona radiata [1]. It can also compromise the splenium of corpus callosum [1], as in our case, and the cerebellum [2, 3]. Many authors suggest that imaging findings change with time, with restricted diffusion seen only in the acute and subacute stages, followed by gliosis and encephalomalacia in the chronic phase [1, 4, 5]. So is the case of our patient.
Different reports demonstrate that the use of MR, and especially DWI images, is a helpful tool in the detection of early methotrexate white matter injury.

Differential Diagnosis List

Final Diagnosis

Methotrexate-induced leukoencephalopathy

URL:	https://www.eurorad.org/case/11666
DOI:	10.1594/EURORAD/CASE.11666
ISSN:	1563-4086